Brain, Vol. 124, No. 9, 1743-1753,
September 2001
© 2001 Oxford University Press
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis
1 Departments of Research and 2 Neurology, University Hospitals Basel, Switzerland and the 3 Department of Pathology, Division of Neuropathology, University Hospital Vrije Universiteit, MS Centre for Research and Care, The Netherlands
Correspondence to:
Dr R. L. P. Lindberg, Departments of Research and Neurology, University Hospitals, Pharmazentrum, Klingelbergstrasse 50, CH-4056 Basel, Switzerland E-mail: Raija.Lindberg@unibas.ch
In multiple sclerosis, matrix metalloproteinases (MMPs) are effectors of crucial pathogenetic steps, such as blood–brain barrier breakdown, invasion of brain parenchyma by immune cells and demyelination. However, only limited data are available on the types of MMPs induced in the course of multiple sclerosis, and on the role of their endogenous antagonists, the tissue inhibitors of metalloproteinases (TIMPs). We quantified the transcriptional expression of six MMPs and the four TIMPs in lesions and in normal appearing white matter (NAWM) from post-mortem multiple sclerosis brain tissue by real-time polymerase chain reaction, and compared levels with those in brain tissue from six control patients without neurological disease. The mRNA expression of MMP-7 and -9, but not of other metalloproteinases [MMP-2 and -3, and tumour necrosis factor (TNF)-
-converting-enzyme] was equally upregulated throughout all stages of lesion formation with active inflammation, and in most of matched NAWM tissue. The transcription of cytokines TNF-/ß and IL (interleukin)-2, known modulators of MMPs, was upregulated only in distinct stages of lesion formation, while their receptors were not induced at all, which suggests that additional signalling molecules participate in the sustained upregulation of MMP-7 and -9 in multiple sclerosis. None of the TIMPs showed a significant induction over baseline expression of controls. We hypothesize that an imbalance between MMP and TIMP expression may cause a persistent proteolytic overactivity in multiple sclerosis, that may be a factor for continuous tissue destruction, and hence for secondary disease progression.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. R. Folgueras, A. Fueyo, O. Garcia-Suarez, J. Cox, A. Astudillo, P. Tortorella, C. Campestre, A. Gutierrez-Fernandez, M. Fanjul-Fernandez, C. J. Pennington, et al. Collagenase-2 Deficiency or Inhibition Impairs Experimental Autoimmune Encephalomyelitis in Mice J. Biol. Chem., April 4, 2008; 283(14): 9465 - 9474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial Arch Neurol, February 1, 2008; 65(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Colognato, J. Galvin, Z. Wang, J. Relucio, T. Nguyen, D. Harrison, P. D. Yurchenco, and C. ffrench-Constant Identification of dystroglycan as a second laminin receptor in oligodendrocytes, with a role in myelination Development, May 1, 2007; 134(9): 1723 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Plumb, S McQuaid, A K Cross, J Surr, G Haddock, R A. Bunning, and M N Woodroofe Upregulation of ADAM-17 expression in active lesions in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 375 - 385. [Abstract] [PDF]
|
|
|
|
 |
|
 T. M. Kauppinen and R. A. Swanson Poly(ADP-Ribose) Polymerase-1 Promotes Microglial Activation, Proliferation, and Matrix Metalloproteinase-9-Mediated Neuron Death J. Immunol., February 15, 2005; 174(4): 2288 - 2296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sastre-Garriga, M Comabella, L Brieva, A Rovira, M Tintore, and X Montalban Decreased MMP-9 production in primary progressive multiple sclerosis patients Multiple Sclerosis, August 1, 2004; 10(4): 376 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bar-Or, R. K. Nuttall, M. Duddy, A. Alter, H. J. Kim, I. Ifergan, C. J. Pennington, P. Bourgoin, D. R. Edwards, and V. W. Yong Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis Brain, December 1, 2003; 126(12): 2738 - 2749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Medana and M. M. Esiri Axonal damage: a key predictor of outcome in human CNS diseases Brain, March 1, 2003; 126(3): 515 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, and D. Leppert IFN{beta} lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS Neurology, January 14, 2003; 60(1): 52 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Scarisbrick, S. I. Blaber, C. F. Lucchinetti, C. P. Genain, M. Blaber, and M. Rodriguez Activity of a newly identified serine protease in CNS demyelination Brain, June 1, 2002; 125(6): 1283 - 1296. [Abstract] [Full Text] [PDF]
|
|